AAAAAA

   
Results: 1-14 |
Results: 14
LETROZOLE, A NEW ORAL AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - DOUBLE-BLIND RANDOMIZED TRIAL SHOWING A DOSE-EFFECT AND IMPROVED EFFICACY AND TOLERABILITY COMPARED WITH MEGESTROL-ACETATE
Authors: DOMBERNOWSKY P SMITH I FALKSON G LEONARD R PANASCI L BELLMUNT J BEZWODA W GARDIN G GUDGEON A MORGAN M FORNASIERO A HOFFMANN W MICHEL J HATSCHEK T TJABBES T CHAUDRI HA HORNBERGER U TRUNET PF
Citation: P. Dombernowsky et al., LETROZOLE, A NEW ORAL AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - DOUBLE-BLIND RANDOMIZED TRIAL SHOWING A DOSE-EFFECT AND IMPROVED EFFICACY AND TOLERABILITY COMPARED WITH MEGESTROL-ACETATE, Journal of clinical oncology, 16(2), 1998, pp. 453-461
FADROZOLE VERSUS MEGESTROL-ACETATE - A DOUBLE-BLIND RANDOMIZED TRIAL IN ADVANCED BREAST-CANCER
Authors: BEZWODA WR GUDGEON A FALKSON G JORDAAN JP GOEDHALS L
Citation: Wr. Bezwoda et al., FADROZOLE VERSUS MEGESTROL-ACETATE - A DOUBLE-BLIND RANDOMIZED TRIAL IN ADVANCED BREAST-CANCER, Oncology, 55(5), 1998, pp. 416-420
A PHASE-III TRIAL COMPARING VOROZOLE (RIVIZOR(TM)) VERSUS AMINOGLUTETHIMIDE IN THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER
Authors: BENGTSSON NO FOCAN C GUDGEON A ILLIGER HJ KHAYAT D MURRAY R NORTIER JWR WAXMAN J ZIELINSKI C
Citation: No. Bengtsson et al., A PHASE-III TRIAL COMPARING VOROZOLE (RIVIZOR(TM)) VERSUS AMINOGLUTETHIMIDE IN THE TREATMENT OF ADVANCED POSTMENOPAUSAL BREAST-CANCER, European journal of cancer, 33, 1997, pp. 656-656
PHASE-II STUDY OF IV NAVELBINE (NVB) AND DOXORUBICIN (DOX) IN PREVIOUSLY UNTREATED ADVANCED BREAST-CANCER (ABC)
Authors: VOROBIOF D GOEDHALS L BARNARDT P GUDGEON A VANDERMERWE A SMITH L MURRAY E PRETORIUS D BASSOMPIERRE P LATEGAN A DELGADO FM LEPAPE I DANEL P BURILLON JP LECOUTURIER S
Citation: D. Vorobiof et al., PHASE-II STUDY OF IV NAVELBINE (NVB) AND DOXORUBICIN (DOX) IN PREVIOUSLY UNTREATED ADVANCED BREAST-CANCER (ABC), European journal of cancer, 33, 1997, pp. 690-690
RETREATING RECURRENT BREAST-CANCER WITH THE SAME CMF-CONTAINING REGIMEN USED AS ADJUVANT THERAPY
Authors: CASTIGLIONEGERTSCH M TATTERSALL M HACKING A GOLDHIRSCH A GUDGEON A GELBER RD LINDTNER J COATES A COLLINS J ISLEY M SENN HJ RUDENSTAM CM
Citation: M. Castiglionegertsch et al., RETREATING RECURRENT BREAST-CANCER WITH THE SAME CMF-CONTAINING REGIMEN USED AS ADJUVANT THERAPY, European journal of cancer, 33(14), 1997, pp. 2321-2325
DOUBLING EPIRUBICIN DOSE INTENSITY (100 MG M(2) VERSUS 50 MG/M(2)) INTHE FEC REGIMEN SIGNIFICANTLY INCREASES RESPONSE RATES - AN INTERNATIONAL RANDOMIZED PHASE-III STUDY IN METASTATIC BREAST-CANCER/
Authors: BRUFMAN G COLAJORI E GHILEZAN N LASSUS M MARTONI A PEREVODCHIKOVA N TOSELLO C VIARO D ZIELINSKI C KRAINER M SALZER H SCHULLER J DITTRICH C SCHEITHAUER W ZAMAGNI C AMBROSINI G COLUCCI G GENTILINI P ZANIBONI A PACINI P BIANCO R MUSTACCHI G DAPRILE M DEMATTEIS A OLIVEIRA C JORDAAN J GUDGEON A VANZYL J RAKOWSKY E INBAR M RATH P COHEN Y SHANI A FRIED G HEGG R NETO AB BADER G BRAGA RF VITOC C PUERTO VML VALLE AE SALAZAR JD SANCHEZ JC VILLELA GM FOUNTZILAS G
Citation: G. Brufman et al., DOUBLING EPIRUBICIN DOSE INTENSITY (100 MG M(2) VERSUS 50 MG/M(2)) INTHE FEC REGIMEN SIGNIFICANTLY INCREASES RESPONSE RATES - AN INTERNATIONAL RANDOMIZED PHASE-III STUDY IN METASTATIC BREAST-CANCER/, Annals of oncology, 8(2), 1997, pp. 155-162
EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN COMBINATION WITH TAMOXIFEN FOR NODE-POSITIVE POSTMENOPAUSAL BREAST-CANCER PATIENTS
Authors: CASTIGLIONEGERTSCH M GOLDHIRSCH A GUSTERSON B BETTELHEIM R REED R GUSSET H GEISER K HURNY C BERNHARD J HANGARTNER A MAIBACH R PEDOWSKI R GELBER R PRICE K PETERSON H ZELEN M ISLEY M HINKLE R KAY RG HOLDAWAY IM HARVEY VJ JAGUSCH MF NEAVE L MASON BM EVANS B BENJAMIN CS CARTER JF GILLMAN JC MACK D BENSONCOOPER D MONFARDINI S GALLIGIONI E CRIVELLARI D BUONADONNA A MASSARUT S ROSSI C CANDIANI E CARBONE A VOLPE R TROVO MG RONCADIN M SANTINI GF VILLALTA D CORAN F MORASSUT S MARINI G SIMONCINI E MARPICATI P ZANIBONI A SARTORI U BARNI A CERUTTI L ALGHISI A RAFFAGLIO E GARATTINI MP ALBERTINI A GRIGOLATO F MORASSI L BERGONZINI R LAURIOLA C GUDGEON A DENT DM TILTMAN A HACKING A DOWDLE E STEYNOR P TOOP J SCHNURCH HG MOSNY D BENDER HG BOJAR H VERONESI A FOLADORE S PAMICH G BIANCHI G TORRETTA A RUDENSTAM CM WALLGREN A PERSSON S MATTSSON J CAHLIN E HAFSTROM LO HOLMBERG S HULTBORN R COLLDAHLJADERSTROM G GUSTAVSSON B CARLSSON G IVARSSON L THOREN O RUUSVIK O NICKLASSON LG DAHLIN S KARLSSON G LINDBERG B SUNDBACK A BERGEGARDH S SALANDER H ANDERSSON C HESSMAN Y NELZEN O HEIDEMAN M RAMHULT T SVENSSON JH LIDBERG P BJORK S LINDTNER J ERZEN D CERAR O STABUC B GOLOUH R LAMOVEC J SEBEK S KRAMBERGER M VRHOVEC I CORTESFUNES H MARTINEZTELLO F MENDIOLA C CRUZVIGO F LARRODERA ML SIERRA A MIRANDA P ALONSO S COLLINS J SNYDER R GREGORY P BURAS WI GREEN M GALE T HENDERSON M HART S NEIL S KITCHEN P LOVELL R MCLENNAN R REED R RUSSELL I SCHWARZ M BASSER R ROBERTSON A GILL P CARTER ML MALYCHA P YEOH E WARD G LEONG ASY LOMMAXSMITH J HOOSFALL D DANGELO R BYRNE M VANHAZEL G DEWAR J BUCK M SHEINER HJ INGRAM D STERRETT G HAHNEL R FORBES JF STEWARD J DARBAR SW BISHOP JM SIMMS B ZIOGAS V TATTERSALL MHN COATES A NIESCHE F WEST R RENWICK S DONOVAN J DUVAL P SIMES RJ NG A GLENN D NORTH RA BEITH J OCONNOR RG RICE M STEVENS G FEY M BARTH A DREHER E ISENSCHMID M SCHNEIDER H BUSER K LUDIN J LUTHI JM ALTERMATT HJ LAISSUE JA MARKWALDER R BURGI H SENN HJ THURLIMANN B JUNGI WF MORANT R OEHLSCHLEGEL C HARDMEIER T LUSCHER K RIES G TOPFER M LORENZ U BENZ D SCHILTKNECHT O SPATI B SCHMID L CAVALLI F SESSA C BRONZ L MARTINELLI G MULLER W LUSCIETI P PASSEGA E PEDRINIS E REY P MARTINOLI S SPINELLI A GALFETTI MA LOMBARDI A PEDRAZZINI A LOSA G VARINI M GINIER M HERRMANN R HARDER JF LAFFER U ALMENDRAL AC EPPENBERGER U TORHORST J SIEGENTHALER P PIGUET D BARRELET V BAUMANN RP JOSS R SAUTER C METZGER U ENGELER V HALLER U KOCHLI O LEYVRAZ S PEREY L ANANI P GOMEZ F MIRIMANOFF RO CHAPUIS G DEGRANDI P REYMOND P ALBERTO P SCHAFER P KRAUER F FORNI M AAPRO M EGELI R MEGEVAND R JACOTDESCOMBES E SCHINDLER A NOSEDA G WEBER W LEHMANN W
Citation: M. Castiglionegertsch et al., EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN COMBINATION WITH TAMOXIFEN FOR NODE-POSITIVE POSTMENOPAUSAL BREAST-CANCER PATIENTS, Journal of clinical oncology, 15(4), 1997, pp. 1385-1394
A CASE-CONTROL STUDY OF BREAST-CANCER RISK AND EXPOSURE TO INJECTABLEPROGESTOGEN CONTRACEPTIVES - METHODS AND PATTERNS OF USE AMONG CONTROLS
Authors: BAILIE R KATZENELLENBOGEN J HOFFMAN M SCHIERHOUT G TRUTER H DENT D GUDGEON A VANZYL J ROSENBERG L SHAPIRO S
Citation: R. Bailie et al., A CASE-CONTROL STUDY OF BREAST-CANCER RISK AND EXPOSURE TO INJECTABLEPROGESTOGEN CONTRACEPTIVES - METHODS AND PATTERNS OF USE AMONG CONTROLS, South African medical journal, 87(3), 1997, pp. 302-305
THE EFFECT OF ADJUVANT PREDNISONE COMBINED WITH CMF ON PATTERNS OF RELAPSE AND OCCURRENCE OF 2ND MALIGNANCIES IN PATIENTS WITH BREAST-CANCER
Authors: MARINI G MURRAY S GOLDHIRSCH A GELBER RD CASTIGLIONEGERTSCH M PRICE KN TATTERSALL MHN RUDENSTAM CM COLLINS J LINDTNER J CAVALLI F CORTESFUNES H GUDGEON A FORBES JF GALLIGIONI E COATES AS SENN HJ
Citation: G. Marini et al., THE EFFECT OF ADJUVANT PREDNISONE COMBINED WITH CMF ON PATTERNS OF RELAPSE AND OCCURRENCE OF 2ND MALIGNANCIES IN PATIENTS WITH BREAST-CANCER, Annals of oncology, 7(3), 1996, pp. 245-250
HORMONE REPLACEMENT THERAPY IN PATIENTS WHO HAVE HAD BREAST-CANCER
Authors: MURRAY EM DENT D GUDGEON A DEVILLIERS D WERNER ID WOLPE C
Citation: Em. Murray et al., HORMONE REPLACEMENT THERAPY IN PATIENTS WHO HAVE HAD BREAST-CANCER, South African medical journal, 86(10), 1996, pp. 1294-1294
ROUTINE TESTS DURING FOLLOW-UP OF PATIENTS AFTER PRIMARY-TREATMENT FOR OPERABLE BREAST-CANCER
Authors: CRIVELLARI D PRICE KN HAGEN M GOLDHIRSCH A GELBER RD CASTIGLIONE M COATES AS RUDENSTAM CM COLLINS J LINDTNER J CORTESFUNES H GUDGEON A SIMONCINI E BYRNE M SCHNURCH HG FEY M TATTERSALL MHN FORBES JF CAVALLI F SENN HJ
Citation: D. Crivellari et al., ROUTINE TESTS DURING FOLLOW-UP OF PATIENTS AFTER PRIMARY-TREATMENT FOR OPERABLE BREAST-CANCER, Annals of oncology, 6(8), 1995, pp. 769-776
ONDANSETRON COMPARED WITH GRANISETRON IN THE PROPHYLAXIS OF CYCLOPHOSPHAMIDE-INDUCED EMESIS IN OUT-PATIENTS - A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP STUDY
Authors: STEWART A MCQUADE B CRONJE JDE GOEDHALS L GUDGEON A CORETTE L FROGER X TUBIANAHULIN M LAPLAIGE P ROBERTS JT MCRAE J FORSTER J PARASURAMAN TV BUTCHER M
Citation: A. Stewart et al., ONDANSETRON COMPARED WITH GRANISETRON IN THE PROPHYLAXIS OF CYCLOPHOSPHAMIDE-INDUCED EMESIS IN OUT-PATIENTS - A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP STUDY, Oncology, 52(3), 1995, pp. 202-210
THE BEST AVAILABLE ADJUVANT TREATMENTS ARE WITHIN THE FRAMEWORK OF CLINICAL-TRIALS - THE INTERNATIONAL BREAST-CANCER STUDY-GROUP
Authors: GOLDHIRSCH A GELBER RD CASTIGLIONE M PRICE KN RUDENSTAM CM LINDTNER J COLLINS J SENN HJ CAVALLI F GALLIGIONI E FEY M GUDGEON A CORTESFUNES H TATTERSALL M MARINI G BYRNE M SNYDER R FORBES JF KAY R HURNY C THURLIMANN B REED R GUSTERSON B TORHORST J SAVESODERBERGH J COATES A
Citation: A. Goldhirsch et al., THE BEST AVAILABLE ADJUVANT TREATMENTS ARE WITHIN THE FRAMEWORK OF CLINICAL-TRIALS - THE INTERNATIONAL BREAST-CANCER STUDY-GROUP, Israel journal of medical sciences, 31(2-3), 1995, pp. 144-154
PRESENT AND FUTURE PROJECTS OF THE INTERNATIONAL BREAST-CANCER STUDY-GROUP
Authors: GOLDHIRSCH A GELBER RD CASTIGLIONE M PRICE KN RUDENSTAM CM LINDTNER J COLLINS J SENN HJ BRUNNER KW GALLIGIONI E CAVALLI F GUDGEON A CORTESFUNES H TATTERSALL M MARINI G BYRNE M SNYDER R FORBES JF HURNY C COATES A
Citation: A. Goldhirsch et al., PRESENT AND FUTURE PROJECTS OF THE INTERNATIONAL BREAST-CANCER STUDY-GROUP, Cancer, 74(3), 1994, pp. 1139-1149
Risultati: 1-14 |